ESR1 and breast cancer: However, no significant survival difference was detected between ER-negative/PR-positive and ER-negative/PR-negative bone metastatic breast cancer, which suggested that aside from their morphological and molecular similarity (34), they also resemble in aspect of the survival outcome in breast cancer with bone metastases.